NCT03278665View on ClinicalTrials.gov

4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 25, 2017

Primary Completion Date

February 2, 2022

Study Completion Date

February 2, 2022

Conditions

Malignant Melanoma

Interventions

DRUG

4SC-202 in combination with Pembrolizumab

Trial Locations (7)

Unknown

Universitätsklinikum Essen, Essen

Medizinische Hochschule Hannover, Hanover

Universitätsklinikum Heidelberg, Heidelberg

Klinikum der Universität München, München

Universitätsklinikum Tübingen, Tübingen

Universitätsklinikum Würzburg, Würzburg

"Istituto Nazionale Tumori Fondazione G. Pascale", Napoli

All Listed Sponsors

lead

4SC AG

INDUSTRY

NCT03278665 - 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy | Biotech Hunter | Biotech Hunter